HGHermann Josef Girschick

Hermann Josef Girschick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hermann Josef Girschick has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Recombinant Enzyme Replacement Therapy in Hypophosphatasia

    by Christine Hofmann, Franz Jakob, Lothar Seefried, Birgit Mentrup, Stephanie Graser, Horacio Plotkin, Hermann J. Girschick, Johannes Liese

    Hypophosphatasia (HPP) is a rare monogenetic and multisystemic disease with involvement of different organs, including bone, muscle, kidney, lung, gastrointestinal tract and the nervous system. The exact metabolic mechanisms of the effects of TNAP deficiency in different tissues are not understood in detail. There is no approved specific treatment for HPP; therefore symptomatic treatment in order to improve the clinical features is of major interest. Enzyme replacement therapy (ERT) is a relatively new type of treatment based on the principle of administering a medical treatment replacing a defective or absent enzyme. Recently ERT with a bone targeted recombinant human TNAP molecule has been reported to be efficient in ten severely affected patients and improved survival of life threatening forms. These results are very promising especially with regard to the skeletal phenotype but it is unclear whether ERT also has beneficial effects for craniosynostosis and in other affected tissues in HPP such as brain and kidney. Long-term data are not yet available and further systematic clinical trials are needed. It is also necessary to establish therapeutic approaches to help patients who are affected by less severe forms of HPP but also suffer from a significant reduction in quality of life. Further basic research on TNAP function and role in different tissues and on its physiological substrates is critical to gain a better insight in the pathogenesis in HPP. This and further experiences in new therapeutic strategies may improve the prognosis and quality of life of patients with all forms of HPP.


  • Seltene autoinflammatorische Knochenerkrankungen

    by F. Jakob, H. J. Girschick, H. Morbach, C. Hofmann

    Zusammenfassung: Autoinflammatorische Knochenerkrankungen sind gekennzeichnet durch eine entzündliche zelluläre Infiltration des Knochens, Osteoklastenaktivierung, Osteolyse und gesteigertes Knochenremodelling infolge einer aberranten Aktivierung des angeborenen Immunsystems. Der Knochenabbau infolge chronischer Osteomyelitis zeigt die enge Verknüpfung zwischen Immun- und Skelett system. Die Identifizierung von definierten molekularen Defekten bei verschiedenen Erkrankungen konnte bereits zu einem besseren Verständnis der komplexen Interaktion zwischen Knochen und Immunsystem beitragen. Die sporadisch auftretende chronische nichtinfektiöse Osteomyelitis stellt die am häufigsten vorkommende Erkrankung dar. Zu den seltenen monogenetischen autoinflammatorischen Erkrankungen zählen: IL-1- Rezeptorantagonist-Mangel, Majeed-Syndrom und Cherubism. Weitere der sogenannten Inflammasom- und auch Stoffwechsel-erkrankungen aufgrund von Enzymdefekten (Hypophosphatasie, hypertrophe Osteoarthropathie) beeinhalten eine signifikante inflammatorisch bedingte Knochenpathologie. Im folgenden Artikel werden diese seltenen Erkrankungen von den molekularen Pathologien bis hin zur klinischen Präsentation diskutiert. Ein besseres Verständnis der pathophysiologischen Grundlagen von autoinflammatorischen Knochenerkrankungen könnte zur Entwicklung weiterer gezielter Therapieansätze beitragen, wovon letztlich auch Patienten mit häufiger vorkommenden Knochenerkrankungen profitieren.

  • Clinical Aspects of Hypophosphatasia: An Update

    by C. Hofmann, H. J. Girschick, B. Mentrup, S. Graser, L. Seefried, J. Liese, F. Jakob


  • Crohn’s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature

    by V. Wiegering, H. Morbach, A. Dick, H. J. Girschick

    Tumor necrosis factor alpha (TNFα) has broad effects on the immune system including lymphoid organ development as well as growth, survival und function of immune cells. TNFα has two main functions: regulatory effects and proinflammatory activities. In several diseases such as juvenile and adult “rheumatoid” arthritis, psoriasis and chronic inflammatory bowel disease, the application of TNFα-blocking medications has been beneficial. However, induction of inflammation in several organs including the eye, CNS, skin and gastrointestinal tract has been reported. We report on an 11-year-old girl with juvenile idiopathic arthritis, who developed Crohn’s disease (CD) while taking etanercept for her arthritis. Etanercept was discontinued and an antibody-based anti-TNF treatment using adalimumab was started, which induced remission of the gastrointestinal symptoms promptly. This case indicates that immunodysregulatory and even proinflammatory effects of etanercept are of relevance in the clinical practice. Furthermore, TNFα as a part of its function seems to downregulate mucosal inflammation in CD.


  • Open Access

    Hypophosphatasia - Recent Advances in Diagnosis and Treatment

    by Beck C., Morbach H., Stenzel M., Collmann H., Schneider P., Girschick H. J.

    Hypophosphatasia – Recent Advances in Diagnosis and Treatment


  • Tumor necrosis factor receptor 1-associated periodic syndrome without fever: cytokine profile before and during etanercept treatment

    by H. Morbach, P. Richl, S. Stojanov, P. Lohse, Hermann J. Girschick

    The objectives of this study are autoinflammatory syndromes which are usually characterized by repeated attacks of fever, especially in children. The presentation of these diseases, however, varies between entities and between patients of a particular syndrome. We report a 16-year-old female patient, who suffered from periodic erythema and myositis/fasciitis. She experienced at least nine attacks of dermatitis and myositis, while no fever episodes were noted over a 3-year period. A delay of puberty with amenorrhea and a short stature were also present. Laboratory investigations consistently showed markedly increased inflammatory parameters (especially a high serum amyloid A) and dysproteinemia. Because the patient′s mother complained about chronic and periodic abdominal pain with also persistently elevated inflammatory parameters, the differential diagnosis included hereditary disorders resulting in chronic inflammation. The diagnosis of an inherited tumor necrosis factor receptor (TNFR) 1-associated periodic syndrome (TRAPS) was confirmed by genetic analyses. Long-term anti-inflammatory treatment with etanercept resulted in a significant clinical improvement and reduction of the inflammatory parameters ESR, CRP, interleukin-6, TNF-α, and soluble TNF-α receptor 1, but not of interleukin-12. Monitoring of the cytokine profile suggested partial effectiveness of etanercept in the treatment of TRAPS. Hereditary fever syndromes have to be considered in case of chronic unexplained inflammation even if fever is no presenting symptom.


  • Open Access

    Treatment of Lyme borreliosis

    by Hermann J Girschick, Henner Morbach, Dennis Tappe

    Borrelia burgdorferi sensu lato is the causative agent of Lyme borreliosis in humans. This inflammatory disease can affect the skin, the peripheral and central nervous system, the musculoskeletal and cardiovascular system and rarely the eyes. Early stages are directly associated with viable bacteria at the site of inflammation. The pathogen-host interaction is complex and has been elucidated only in part. B. burgdorferi is highly susceptible to antibiotic treatment and the majority of patients profit from this treatment. Some patients develop chronic persistent disease despite repeated antibiotics. Whether this is a sequel of pathogen persistence or a status of chronic auto-inflammation, auto-immunity or a form of fibromyalgia is highly debated. Since vaccination is not available, prevention of a tick bite or chemoprophylaxis is important. If the infection is manifest, then treatment strategies should target not only the pathogen by using antibiotics but also the chronic inflammation by using anti-inflammatory drugs.


  • How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases?

    by C. Beck, H. Morbach, P. Richl, M. Stenzel, H. J. Girschick

    Hypophosphatasia (HP) is a rare inborn error of bone and mineral metabolism characterized by a defect in the tissue non-specific alkaline phosphatase (TNSALP) gene. Calcium pyrophosphate dihydrate (CPPD) crystals are known to accumulate as substrates of TNSALP in tissues and joints of patients with HP. In CPPD-induced arthritis these crystals are known to induce an inflammatory response. HP patients do suffer from pain in their lower extremities. However, it is not clear whether CPPD crystals contribute to these musculoskeletal complaints in HP. As long as there is no curative treatment of HP, symptomatic treatment in order to improve clinical features, especially with regard to pain and physical activity, is of major interest to the patients. Knowledge of the mechanisms underlying crystal-induced cell activation, however, is limited. Here we describe recent advances in elucidating the signal transduction pathways activated by CPPD crystals as endogenous “danger signals”. Recent investigations provided evidence that Toll/interleukin-1 receptor (TIR) domain containing receptors including Toll-like receptors (TLRs) and interleukin-1 receptor (IL-1R), as well as the triggering receptor expressed on myeloid cells 1 (TREM-1) and the NACHT-leucin rich repeat and pyrin-domain-containing protein (NALP3) containing inflammasome are essentially involved in acute CPPD crystal-induced inflammation. These receptors are considered in part as components of the innate immune system. Further studies are needed to improve our understanding of the pathophysiological mechanisms leading to inflammation and tissue destruction associated with deposition of microcrystals. They might support the development of new therapeutic strategies for crystal-induced inflammation. Eventually, patients with HP might as well profit from such strategies addressing these metabolic disorders secondary to the gene defect.


  • Abscess-forming lymphadenopathy and osteomyelitis in children with Bartonella henselae infection

    by Regina Ridder-Schröter, Aleander Marx, Meinrad Beer, Dennis Tappe, Hans-Wolfgang Kreth, Hermann J. Girschick

    Bartonella henselaeis the agent of cat-scratch disease (CSD), a chronic lymphadenopathy among children and adolescents. A systemic infection is very rare and most of these cases are found in patients with immunodeficiency. Here, cases involving four children of 6–12 years of age are reported. Three of the children had an abscess-forming lymphadenopathy and surrounding myositis in the clavicular region of the upper arm. The diagnosis was made serologically and, in one case, using eubacterial universal PCR. One child was treated with erythromycin for 10 days, the second received cefotaxime and flucloxacillin for 14 days and the third child was not treated with antibiotics. The fourth child had a different course: a significantly elevated signal intensity affecting the complete humerus was found in magnetic resonance imaging, consistent with osteomyelitis. A lymph node abscess was also found in the axilla. Diagnosis was established by indirect fluorescence assay and lymph node biopsy. Antibiotic therapy using clarithromycin, clindamycin and rifampicin was gradually successful. Immunodeficiency was excluded. All described lesions healed without residues. In immunocompetent patients, infection affects skin and draining lymph nodes; however, prolonged fever of unknown origin as in the fourth patient indicated a systemic complication of CSD.